SBI Securities’s Actinium Pharmaceuticals ATNM Stock Holding History

SBI Securities’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$482	Sell	492 -50	-9%	-$58	﹤0.01%	3044
2026 Q1	$539	Hold	542	–	–	﹤0.01%	2868
2025 Q4	$737	Hold	542	–	–	﹤0.01%	2741
2025 Q3	$867	Hold	542	–	–	﹤0.01%	2759
2025 Q2	$759	Hold	542	–	–	﹤0.01%	2794
2025 Q1	$873	Hold	542	–	–	﹤0.01%	2645
2024 Q4	$683	Buy	+542	New	+$841	﹤0.01%	2772

Other funds holding ATNM

AIS

AM Investment Strategies Chattanooga, Tennessee $521M AUM 33.22% 1-Year Est. Return

PAI

Pittenger & Anderson Inc Lincoin, Nebraska $2.79B AUM 12.81% 1-Year Est. Return

IRC

Investors Research Corp Atlanta, Georgia $559M AUM 21.55% 1-Year Est. Return

APW

Allied Private Wealth Boca Raton, Florida $156M AUM

AIM

Axiom Investment Management New York $150M AUM

SBI Securities's ATNM Position: Q2 2026 in Review

SBI Securities reduced its Actinium Pharmaceuticals (ATNM) stake by 9.2% in Q2 2026, selling an estimated $58 and leaving 492 shares worth $482. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

SBI Securities first reported a position in ATNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $873 in Q1 2025. 6 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

SBI Securities held 492 shares of Actinium Pharmaceuticals worth $482 as of Q2 2026.
SBI Securities sold 50 Actinium Pharmaceuticals shares in Q2 2026, an estimated $58.
Actinium Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3044 holding.
SBI Securities first reported a position in Actinium Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Actinium Pharmaceuticals position peaked at $873 in Q1 2025.
6 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.